A global digital navigator of human health for precision medicine - Nature

Demand for electrification is moving faster than the system it connects to. Electric vehicles, heat pumps and electrified industrial processes are scaling1, and the the United Nations Climate Change Conference (COP31) Presidency has set a global target of 35% of final energy demand met by electricity by 2035, up from around 21% today.2 What now sets the pace is the readiness of the power system, which means how fast projects connect, whether prices reward flexibility, and whether equipment and markets work together. For businesses, electrification is increasingly a decision about competitiveness, resilience and long-term value creation. The companies and markets that can electrify faster are often better positioned to manage energy costs, access new revenue streams, strengthen operational resilience and attract investment. Businesses across every sector describe the same set of barriers: connection queues running for years, tariffs that do not support the business case and hold flat while system costs move hour by hour, fragmented market structures with missing aggregation rules and interoperability standards, and flexible capacity waiting for a market to sell into.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.